Abstract Details

Title Neuroprotective Effect of Pre-Stroke Statin Therapy in a Cohort of Elderly Ischemic Stroke Patients

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P03 - (-)

Poster/Presentation
Number 195

Objective

Background BACKGROUND: Although statin therapy has shown to be effective in ischemic stroke prevention and recent clinical reports demonstrated better clinical outcomes and mortality reduction in patients under pre-stroke statin treatment, data in elderly patients are scarce.

Design/Methods DESIGN/METHODS: All ischemic stroke patients admitted to Hospital Italiano between January/ 2007 to April/ 2012 were prospectively included in the analysis, and demographic data, main vascular risk factors profile and control, and outcomes one month after stroke were evaluated.

Results RESULTS: 1053 patients were included; mean age 75±10 years, 57% were female and 46% older than 80 years-old. Main vascular risk factors were hypertension (83%), dyslipemia (70%), metabolic syndrome (46%) and obesity (42%). Forty percent of patients were under statin treatment before stroke (n:409). Patients older than 80 years under statin treatment before stroke had better functional outcome than those who were not (m-Rankin <3: 80% vs 70%; Barthel index 90 ± 16 vs 85 ± 22) and better cognitive function one month after stroke (abnormal MMSE 20% vs 30%). There were no differences in mortality and recurrence rate between both groups.

Conclusions CONCLUSIONS: Pre-stroke statin treatment is strongly associated with improved functionality and cognition in elderly patients. Mortality and recurrence rates were similar in all patients, independently of pre-stroke statin treatment.

Authors/Disclosures
PRESENTER	No disclosure on file
Maria C. Zurru, MD	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Edgardo Cristiano, MD (Hospital Italiano De Buenos Aires)	Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
	No disclosure on file

��ɫ��

��ɫ��